Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Avanafil

FDA-approved product (tablet, oral), marketed as Avanafil, Stendra.

Registered studies
24
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Avanafil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Erectile dysfunction
  • Impotence

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Drugs used in erectile dysfunction
FDA pharmacologic class
Phosphodiesterase 5 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

24registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Avanafil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Avanafil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Daily Avanafil for Erectile Dysfunction

    NCT04374994 · start 2018-09-01

    Registered record
    Registry ID
    NCT04374994
    Conditions
    Erectile Dysfunction
    Interventions
    Avanafil 50 MG; Placebo oral tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-09-01
    Completion
    2019-10-10
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    InterventionAvanafil 50 MG; Placebo oral tablet
    PhasePhase 4
    Registry statusCompleted

  • Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction

    NCT03169582 · start 2016-04-01

    Registered record
    Registry ID
    NCT03169582
    Conditions
    Erectile Dysfunction
    Interventions
    Avanafil; Sildenafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-04-01
    Completion
    2018-06-01
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    InterventionAvanafil; Sildenafil
    PhasePhase 4
    Registry statusUnknown

  • Efficacy and Tolerability Study of Avanafil in Russia

    NCT02503306 · start 2015-07

    Registered record
    Registry ID
    NCT02503306
    Conditions
    Sexual Function and Fertility Disorders NEC-Erectile Dysfunction
    Interventions
    AVANAFIL; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-07
    Completion
    2016-03
    Enrolment
    189

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSexual Function and Fertility Disorders NEC-Erectile Dysfunction
    InterventionAVANAFIL; placebo
    PhasePhase 3
    Registry statusCompleted

  • Safety Study Looking at the Effects of Stendra on Vision

    NCT02033200 · start 2014-01

    Registered record
    Registry ID
    NCT02033200
    Conditions
    Vision
    Interventions
    Stendra 200 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-01
    Completion
    2014-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVision
    InterventionStendra 200 mg; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Study Evaluating the Effects of Avanafil on Semen Parameters

    NCT01768676 · start 2012-12

    Registered record
    Registry ID
    NCT01768676
    Conditions
    Erectile Dysfunction
    Interventions
    avanafil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-12
    Completion
    2014-08
    Enrolment
    181

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    Interventionavanafil; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction

    NCT01698684 · start 2012-09

    Registered record
    Registry ID
    NCT01698684
    Conditions
    Erectile Dysfunction
    Interventions
    Placebo; Avanafil 100 mg; Avanafil 200 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-09
    Completion
    2013-04
    Enrolment
    440

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    InterventionPlacebo; Avanafil 100 mg; Avanafil 200 mg
    PhasePhase 4
    Registry statusCompleted

  • This Study is to Evaluate the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction.

    NCT01705197 · start 2012-02

    Registered record
    Registry ID
    NCT01705197
    Conditions
    Erectile Dysfunction
    Interventions
    Avanafil 100 or 200mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-02
    Completion
    2013-11
    Enrolment
    195

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    InterventionAvanafil 100 or 200mg
    PhasePhase 3
    Registry statusCompleted

  • Study the Effect of Avanafil on the Pharmacodynamics and Pharmacokinetics of Warfarin in Healthy Male Subjects

    NCT01095588 · start 2010-04

    Registered record
    Registry ID
    NCT01095588
    Conditions
    Erectile Dysfunction
    Interventions
    200 mg Avanafil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-04
    Completion
    2010-05
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    Intervention200 mg Avanafil; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Assess the Effect of Food on Avanafil Pharmacokinetic (PK), to Compare 2 Oral Formulations of Avanafil,and Investigate Dose Proportionality in Healthy Male Subjects

    NCT01095601 · start 2010-04

    Registered record
    Registry ID
    NCT01095601
    Conditions
    Healthy
    Interventions
    Avanafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-04
    Completion
    2010-05
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAvanafil
    PhasePhase 1
    Registry statusCompleted

  • Drug Interaction Study of Avanafil and Enalapril or Amlodipine

    NCT01117038 · start 2010-04

    Registered record
    Registry ID
    NCT01117038
    Conditions
    Erectile Dysfunction
    Interventions
    avanafil and enalapril; avanafil and amlodipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-04
    Completion
    2010-05
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    Interventionavanafil and enalapril; avanafil and amlodipine
    PhasePhase 1
    Registry statusCompleted

  • Compare the Pharmacokinetics of Omeprazole, Rosiglitazone, and Desipramine When Administered With Avanafil in Healthy Male Subjects

    NCT01415128 · start 2010-04

    Registered record
    Registry ID
    NCT01415128
    Conditions
    Erectile Dysfunction
    Interventions
    Omeprazole; Rosiglitazone; Desipramine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-04
    Completion
    2010-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    InterventionOmeprazole; Rosiglitazone; Desipramine
    PhasePhase 1
    Registry statusCompleted

  • Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin

    NCT01100021 · start 2010-02

    Registered record
    Registry ID
    NCT01100021
    Conditions
    Erectile Dysfunction
    Interventions
    Tamsulosin and avanafil; Doxazosin and avanafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-02
    Completion
    2010-04
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    InterventionTamsulosin and avanafil; Doxazosin and avanafil
    PhasePhase 1
    Registry statusCompleted

  • To Compare the Pharmacokinetics of Avanafil in Subjects With Mild and Moderate Renal Impairment to Subjects With Normal Renal Function.

    NCT01054261 · start 2010-01

    Registered record
    Registry ID
    NCT01054261
    Conditions
    Renal
    Interventions
    avanafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-02
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal
    Interventionavanafil
    PhasePhase 1
    Registry statusCompleted

  • To Assess the Safety of Avanafil in Healthy and Hepatically Impaired Male Subjects.

    NCT01054430 · start 2010-01

    Registered record
    Registry ID
    NCT01054430
    Conditions
    Erectile Dysfunction
    Interventions
    avanafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-02
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    Interventionavanafil
    PhasePhase 1
    Registry statusCompleted

  • A Phase I Crossover Study of the Hemodynamic Interactions of Avanafil & Alcohol in Healthy Male Subjects.

    NCT01054859 · start 2010-01

    Registered record
    Registry ID
    NCT01054859
    Conditions
    Erectile Dysfunction
    Interventions
    avanafil; alcohol; avanafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    Interventionavanafil; alcohol; avanafil
    PhasePhase 1
    Registry statusCompleted